1.	A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Phase: Phase IV Type: Supportive care Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: V99C1-026, IRB:98-09-09, NCT01298284
2.	ß-adrenergic Blocker and a COX2 Inhibitor for Prevention of Colorectal Cancer Recurrence Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SHEBA-09-6994-OZ-CTIL, NCT00888797
3.	Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VT1-CAX-200, NCT01265576
4.	Bevacizumab vs Dacarbazine in Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2012/910, NCT01705392
5.	Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery: an Intervention to Decrease Immune Suppression, Metastatic Potential and Cancer Recurrence Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 20 to 75 Sponsor: Other Protocol IDs: 392-22.6.07 / 2358, NCT00502684
6.	Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients Phase: No phase specified Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-0447 / 201104047, NCT01308944
7.	Beta-Blocker / Ovarian Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2011-0800, NCT01504126